<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02207920</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 105</org_study_id>
    <secondary_id>11986</secondary_id>
    <nct_id>NCT02207920</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults</brief_title>
  <official_title>A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and immune response to different&#xD;
      combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E&#xD;
      vaccine-in healthy adults who are not infected with HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the&#xD;
      combination of two different experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the&#xD;
      AIDSVAX® B/E vaccine-administered in different sequences or simultaneously, in healthy adults&#xD;
      who are not infected with HIV.&#xD;
&#xD;
      Participants will be randomly assigned to four groups. Depending on which group participants&#xD;
      are in, they will receive different combinations of the DNA-HIV-PT123 vaccine, the AIDSVAX®&#xD;
      B/E vaccine, a placebo for DNA-HIV-PT123 vaccine, and/or a placebo for AIDSVAX® B/E vaccine.&#xD;
      Study visits will occur at study entry, Week 2, and Months 1, 1.5, 3, 3.5, 6, 6.5, 9, and 12.&#xD;
      All participants will receive their assigned combinations of vaccines at study entry and&#xD;
      Months 1, 3, and 6. At each vaccination visit, participants will receive one injection in&#xD;
      each upper arm. Following each vaccination, participants will remain in the clinic for 30&#xD;
      minutes for monitoring. All study visits will include a physical examination, HIV risk&#xD;
      reduction counseling, and questionnaires and assessments. Select study visits will also&#xD;
      include a urine collection, a blood collection, a pregnancy test for participants who were&#xD;
      born female, and HIV testing and counseling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of local and systemic reactogenicity signs and symptoms</measure>
    <time_frame>Measured through Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measure of safety: measurement of complete blood count (CBC)</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>Including differential and platelets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measure of safety: measurement of alanine aminotransferase (ALT)</measure>
    <time_frame>Measured through Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measure of safety: measurement of creatinine</measure>
    <time_frame>Measured through Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>Measured through Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of serious adverse events (SAEs)</measure>
    <time_frame>Measured through Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-specific binding antibody (Ab) response as assessed by binding Ab multiplex assay</measure>
    <time_frame>Measured 2 weeks after the 4th vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate and magnitude of CD4 T cell responses as assessed by intracellular cytokine staining (ICS) assays</measure>
    <time_frame>Measured 2 weeks after the 4th vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate and magnitude of CD8 T cell responses as assessed by ICS assays</measure>
    <time_frame>Measured 2 weeks after the 4th vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody (nAb) magnitude and breadth against tier 1 and tier 2 HIV-1 isolates as assessed by area under the magnitude-breadth curves</measure>
    <time_frame>Measured 2 weeks after the 4th vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-specific Ab and T-cell responses</measure>
    <time_frame>Measured 6 months after the 4th vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At study entry and Month 1, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.&#xD;
At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.&#xD;
At Months 3 and 6, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.&#xD;
At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At study entry and Months 1, 3, and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIDSVAX B/E Vaccine</intervention_name>
    <description>600 mcg/mL to be administered as 1 mL intramuscular (IM) injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA-HIV-PT123 Vaccine</intervention_name>
    <description>4 mg/mL to be administered as 1 mL IM injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for DNA-HIV-PT123</intervention_name>
    <description>Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for AIDSVAX B/E</intervention_name>
    <description>Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General and Demographic Criteria&#xD;
&#xD;
          -  Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site&#xD;
             (CRS) and willingness to be followed for the planned duration of the study&#xD;
&#xD;
          -  Ability and willingness to provide informed consent&#xD;
&#xD;
          -  Assessment of understanding: participant demonstrates understanding of this study;&#xD;
             completes a questionnaire prior to first vaccination, with verbal demonstration of&#xD;
             understanding of all questionnaire items answered incorrectly&#xD;
&#xD;
          -  Agrees not to enroll in another study of an investigational research agent before the&#xD;
             last required protocol clinic visit&#xD;
&#xD;
          -  Good general health as shown by medical history, physical exam, and screening&#xD;
             laboratory tests&#xD;
&#xD;
        HIV-Related Criteria:&#xD;
&#xD;
          -  Willingness to receive HIV test results&#xD;
&#xD;
          -  Willingness to discuss HIV infection risks and amenable to HIV risk reduction&#xD;
             counseling&#xD;
&#xD;
          -  Assessed by the clinic staff as being at &quot;low risk&quot; for HIV infection and committed to&#xD;
             maintaining behavior consistent with low risk of HIV exposure through the last&#xD;
             required protocol clinic visit&#xD;
&#xD;
        Laboratory Inclusion Values&#xD;
&#xD;
        Hemogram/Complete Blood Count (CBC)&#xD;
&#xD;
          -  Hemoglobin greater than or equal to 11.0 g/dL for participants who were born female;&#xD;
             greater than or equal to 13.0 g/dL for participants who were born male&#xD;
&#xD;
          -  White blood cell count equal to 3,300 to 12,000 cells/mm^3&#xD;
&#xD;
          -  Total lymphocyte count greater than or equal to 800 cells/mm^3&#xD;
&#xD;
          -  Remaining differential either within institutional normal range or with site physician&#xD;
             approval&#xD;
&#xD;
          -  Platelets equal to 125,000 to 550,000/mm^3&#xD;
&#xD;
        Chemistry&#xD;
&#xD;
          -  Chemistry panel: alanine aminotransferase (ALT) less than 1.25 times the institutional&#xD;
             upper limit of normal (IULN) and creatinine less than or equal to IULN&#xD;
&#xD;
        Virology&#xD;
&#xD;
          -  Negative HIV-1 and -2 blood test: participants must have a negative Food and Drug&#xD;
             Administration (FDA)-approved enzyme immunoassay (EIA)&#xD;
&#xD;
          -  Negative hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
          -  Negative anti-hepatitis C virus (anti-HCV) Abs, or negative HCV polymerase chain&#xD;
             reaction (PCR) if the anti-HCV is positive&#xD;
&#xD;
        Urine&#xD;
&#xD;
          -  Normal urine:&#xD;
&#xD;
               -  Negative urine glucose, and&#xD;
&#xD;
               -  Negative or trace urine protein, and&#xD;
&#xD;
               -  Negative or trace urine hemoglobin (if trace hemoglobin is present on dipstick, a&#xD;
                  microscopic urinalysis with red blood cell levels within institutional normal&#xD;
                  range)&#xD;
&#xD;
        Reproductive Status&#xD;
&#xD;
          -  Participants who were born female: negative serum or urine beta human chorionic&#xD;
             gonadotropin (β-HCG) pregnancy test performed prior to vaccination on the day of&#xD;
             initial vaccination. Persons who are NOT of reproductive potential due to having&#xD;
             undergone total hysterectomy with bilateral oophorectomy (verified by medical records)&#xD;
             are not required to undergo pregnancy testing.&#xD;
&#xD;
          -  Reproductive status: a participant who was born female must:&#xD;
&#xD;
               -  Agree to consistently use effective contraception for sexual activity that could&#xD;
                  lead to pregnancy from at least 21 days prior to enrollment through the last&#xD;
                  required protocol clinic visit;&#xD;
&#xD;
               -  Or not be of reproductive potential, such as having reached menopause (no menses&#xD;
                  for 1 year) or having undergone hysterectomy, bilateral oophorectomy, or tubal&#xD;
                  ligation;&#xD;
&#xD;
               -  Or be sexually abstinent. More information on this criterion is available in the&#xD;
                  protocol.&#xD;
&#xD;
          -  Participants who were born female must also agree not to seek pregnancy through&#xD;
             alternative methods, such as artificial insemination or in vitro fertilization until&#xD;
             after the last required protocol clinic visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Blood products received within 120 days before first vaccination&#xD;
&#xD;
          -  Investigational research agents received within 30 days before first vaccination&#xD;
&#xD;
          -  Body mass index (BMI) greater than or equal to 40; or BMI greater than or equal to 35&#xD;
             with 2 or more of the following: age greater than 45, systolic blood pressure greater&#xD;
             than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, or known&#xD;
             hyperlipidemia&#xD;
&#xD;
          -  Intent to participate in another study of an investigational research agent before the&#xD;
             last required protocol clinic visit&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
        Vaccines and Other Injections&#xD;
&#xD;
          -  HIV vaccine(s) received in a prior HIV vaccine trial. For participants who have&#xD;
             received control/placebo in an HIV vaccine trial, the HVTN 105 Protocol Safety Review&#xD;
             Team (PSRT) will determine eligibility on a case-by-case basis.&#xD;
&#xD;
          -  Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine&#xD;
             trial. Exceptions may be made for vaccines that have subsequently undergone licensure&#xD;
             by FDA. For participants who have received control/placebo in an experimental vaccine&#xD;
             trial, the HVTN 105 PSRT will determine eligibility on a case-by-case basis. For&#xD;
             participants who have received an experimental vaccine(s) more than 5 years ago,&#xD;
             eligibility for enrollment will be determined by the HVTN 105 PSRT on a case-by-case&#xD;
             basis.&#xD;
&#xD;
          -  Live attenuated vaccines other than influenza vaccine received within 30 days before&#xD;
             first vaccination or scheduled within 14 days after injection (e.g., measles, mumps,&#xD;
             and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever)&#xD;
&#xD;
          -  Influenza vaccine or any vaccines that are not live attenuated vaccines and were&#xD;
             received within 14 days prior to first vaccination (e.g., tetanus, pneumococcal,&#xD;
             hepatitis A or B)&#xD;
&#xD;
          -  Allergy treatment with antigen injections within 30 days before first vaccination or&#xD;
             that are scheduled within 14 days after first vaccination&#xD;
&#xD;
        Immune System&#xD;
&#xD;
          -  Immunosuppressive medications received within 168 days before first vaccination. (Not&#xD;
             excluded: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical&#xD;
             corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of&#xD;
             oral/parenteral corticosteroids at doses less than 2 mg/kg/day and length of therapy&#xD;
             less than 11 days, with completion at least 30 days prior to enrollment)&#xD;
&#xD;
          -  Serious adverse reactions to vaccines, including history of anaphylaxis and related&#xD;
             symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.&#xD;
             (Not excluded: a participant who had a nonanaphylactic adverse reaction to pertussis&#xD;
             vaccine as a child)&#xD;
&#xD;
          -  Immunoglobulin received within 60 days before first vaccination&#xD;
&#xD;
          -  Autoimmune disease (Not excluded: mild, well-controlled psoriasis)&#xD;
&#xD;
          -  Immunodeficiency&#xD;
&#xD;
        Clinically Significant Medical Conditions&#xD;
&#xD;
          -  Untreated or incompletely treated syphilis infection&#xD;
&#xD;
          -  Clinically significant medical condition, physical examination findings, clinically&#xD;
             significant abnormal laboratory results, or past medical history with clinically&#xD;
             significant implications for current health. More information on this criterion is&#xD;
             available in the protocol.&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or other condition that, in the judgment of&#xD;
             the investigator, would interfere with, or serve as a contraindication to, protocol&#xD;
             adherence, assessment of safety or reactogenicity, or a participant's ability to give&#xD;
             informed consent&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol. Specifically&#xD;
             excluded are persons with psychoses within the past 3 years, ongoing risk for suicide,&#xD;
             or history of suicide attempt or gesture within the past 3 years.&#xD;
&#xD;
          -  Current anti-tuberculosis (TB) prophylaxis or therapy&#xD;
&#xD;
          -  Asthma other than mild or moderate, well-controlled asthma. More information on this&#xD;
             criterion is available in the protocol.&#xD;
&#xD;
          -  Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not&#xD;
             excluded: history of isolated gestational diabetes)&#xD;
&#xD;
          -  Thyroidectomy, or thyroid disease requiring medication during the last 12 months&#xD;
&#xD;
          -  Hypertension:&#xD;
&#xD;
               -  If a participant has been found to have elevated blood pressure or hypertension&#xD;
                  during screening or previously, exclude for blood pressure that is not well&#xD;
                  controlled. Well-controlled blood pressure is defined as consistently less than&#xD;
                  or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic, with&#xD;
                  or without medication, with only isolated, brief instances of higher readings,&#xD;
                  which must be less than or equal to 150 mm Hg systolic and less than or equal to&#xD;
                  100 mm Hg diastolic. For these participants, blood pressure must be less than or&#xD;
                  equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic at&#xD;
                  enrollment.&#xD;
&#xD;
               -  If a participant has NOT been found to have elevated blood pressure or&#xD;
                  hypertension during screening or previously, exclude for systolic blood pressure&#xD;
                  greater than or equal to 150 mm Hg at enrollment or diastolic blood pressure&#xD;
                  greater than or equal to 100 mm Hg at enrollment.&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions)&#xD;
&#xD;
          -  Malignancy (Not excluded: participant who has had malignancy excised surgically and&#xD;
             who, in the investigator's estimation, has a reasonable assurance of sustained cure or&#xD;
             who is unlikely to experience recurrence of malignancy during the period of the study)&#xD;
&#xD;
          -  Seizure disorder: history of seizure(s) within the past 3 years. Also exclude if&#xD;
             participant has used medications in order to prevent or treat seizure(s) at any time&#xD;
             within the past 3 years.&#xD;
&#xD;
          -  Asplenia: any condition resulting in the absence of a functional spleen&#xD;
&#xD;
          -  History of hereditary angioedema, acquired angioedema, or idiopathic angioedema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Keefer</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bridge HIV CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Blood Center CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Vaccines to Prevent HIV Infection CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Prevention CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine (VV) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Vaccine and Prevention CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 31, 2014</study_first_submitted>
  <study_first_submitted_qc>July 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2014</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02207920
org study id: HVTN 105
secondary id: 11986
nct id: NCT02207920
lead sponsor: 
has dmc: Yes
This study will evaluate the safety, tolerability, and immune response to different
      combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E
      vaccine-in healthy adults who are not infected with HIV.
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the
      combination of two different experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the
      AIDSVAX® B/E vaccine-administered in different sequences or simultaneously, in healthy adults
      who are not infected with HIV.

      Participants will be randomly assigned to four groups. Depending on which group participants
      are in, they will receive different combinations of the DNA-HIV-PT123 vaccine, the AIDSVAX®
      B/E vaccine, a placebo for DNA-HIV-PT123 vaccine, and/or a placebo for AIDSVAX® B/E vaccine.
      Study visits will occur at study entry, Week 2, and Months 1, 1.5, 3, 3.5, 6, 6.5, 9, and 12.
      All participants will receive their assigned combinations of vaccines at study entry and
      Months 1, 3, and 6. At each vaccination visit, participants will receive one injection in
      each upper arm. Following each vaccination, participants will remain in the clinic for 30
      minutes for monitoring. All study visits will include a physical examination, HIV risk
      reduction counseling, and questionnaires and assessments. Select study visits will also
      include a urine collection, a blood collection, a pregnancy test for participants who were
      born female, and HIV testing and counseling.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Frequency of local and systemic reactogenicity signs and symptoms
time frame: Measured through Month 12
measure: Laboratory measure of safety: measurement of complete blood count (CBC)
time frame: Measured through Month 12
description: Including differential and platelets
measure: Laboratory measure of safety: measurement of alanine aminotransferase (ALT)
time frame: Measured through Month 12
measure: Laboratory measure of safety: measurement of creatinine
time frame: Measured through Month 12
measure: Frequency of adverse events (AEs)
time frame: Measured through Month 12
measure: Frequency of serious adverse events (SAEs)
time frame: Measured through Month 12
measure: HIV-specific binding antibody (Ab) response as assessed by binding Ab multiplex assay
time frame: Measured 2 weeks after the 4th vaccination
measure: Response rate and magnitude of CD4 T cell responses as assessed by intracellular cytokine staining (ICS) assays
time frame: Measured 2 weeks after the 4th vaccination
measure: Response rate and magnitude of CD8 T cell responses as assessed by ICS assays
time frame: Measured 2 weeks after the 4th vaccination
measure: Neutralizing antibody (nAb) magnitude and breadth against tier 1 and tier 2 HIV-1 isolates as assessed by area under the magnitude-breadth curves
time frame: Measured 2 weeks after the 4th vaccination
measure: Measurement of HIV-specific Ab and T-cell responses
time frame: Measured 6 months after the 4th vaccination
arm group label: Group 1
arm group type: Experimental
description: At study entry and Month 1, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.
arm group label: Group 2
arm group type: Experimental
description: At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.
At Months 3 and 6, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
arm group label: Group 3
arm group type: Experimental
description: At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.
At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
arm group label: Group 4
arm group type: Experimental
description: At study entry and Months 1, 3, and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
intervention type: Biological
intervention name: AIDSVAX B/E Vaccine
description: 600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
arm group label: Group 1
arm group label: Group 2
arm group label: Group 3
arm group label: Group 4
intervention type: Biological
intervention name: DNA-HIV-PT123 Vaccine
description: 4 mg/mL to be administered as 1 mL IM injection
arm group label: Group 1
arm group label: Group 2
arm group label: Group 3
arm group label: Group 4
intervention type: Biological
intervention name: Placebo for DNA-HIV-PT123
description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
arm group label: Group 1
arm group label: Group 2
intervention type: Biological
intervention name: Placebo for AIDSVAX B/E
description: Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
arm group label: Group 1
arm group label: Group 2
arm group label: Group 3
criteria: 
gender: All
minimum age: 18 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Michael Keefer
role: Study Chair
affiliation: University of Rochester
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: HIV Infections
mesh term: Vaccines